Niraparib oral liquid and preparation method thereof

A technology for niraparib oral liquid and oral liquid, which is applied in liquid bottling, pharmaceutical formulation, liquid treatment and other directions, can solve problems such as increased drug toxicity and adverse reactions, and achieves enhancement of drug efficacy and repair of damaged cells. , the effect of reducing nausea

Inactive Publication Date: 2019-08-02
南京瑄宇医药科技有限公司
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If you want to improve the efficacy of the drug by increasing the concentration of the free drug of niraparib, the toxicity of the drug will also increase, which will promote the occurrence of adverse reactions
At present, there is no drug that can both promote the anticancer efficacy of niraparib and reduce its adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Niraparib oral liquid and preparation method thereof
  • Niraparib oral liquid and preparation method thereof
  • Niraparib oral liquid and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] A kind of niraparib oral liquid, comprises the component of following parts by weight:

[0052] Nirapani 10 parts;

[0053] 4 parts of diazepam;

[0054] 3 parts of malt selenium;

[0055] Vitamin E 3 parts;

[0056] 40 parts of filler;

[0057] 3 parts rapeseed oil;

[0058] 4 parts of acetone;

[0059] 150 parts of deionized water;

[0060] Specifically, the filling agent includes a sweetener, a flavoring agent, and a glue agent, and their mass ratio is 2:3:1.

[0061] More specifically, the sweetener is protein sugar;

[0062] The aromatic agent is a composition of lemon essence, apple essence and peppermint oil, and their mass ratio is 1:2:1;

[0063] The glue is sodium alginate.

[0064] The preparation method of above-mentioned niraparib oral liquid comprises the steps:

[0065] (i) Take powdered niraparib, diazepam, vitamin E and malt selenium respectively, pulverize niraparib, diazepam and malt selenium and pass through an 80 mesh sieve, dissolve diaze...

Embodiment 2

[0069] A kind of niraparib oral liquid, comprises the component of following parts by weight:

[0070] Nirapani 12 parts;

[0071] 5 parts of diazepam;

[0072] 4 parts of malt selenium;

[0073] Vitamin E 4 parts;

[0074] 35 parts of filler;

[0075] 4 parts rapeseed oil;

[0076] 5 parts of acetone;

[0077] 145 parts of deionized water;

[0078] Specifically, the filling agent includes a sweetener, a flavoring agent, and a glue agent, and their mass ratio is 3:2:1.

[0079] Specifically, the sweetener is a composition of protein sugar and stevioside, and their mass ratio is 3:1;

[0080] The fragrance is a composition of apple essence and banana essence, and their mass ratio is 1:1;

[0081] The glue is a combination of methylcellulose, sodium carboxymethylcellulose and sodium alginate, and their mass ratio is 1:1:2.

[0082] The preparation method of above-mentioned niraparib oral liquid comprises the steps:

[0083] (i) Take powdered niraparib, diazepam, vitami...

Embodiment 3

[0087] A kind of niraparib oral liquid, comprises the component of following parts by weight:

[0088] 15 parts of Nirapani;

[0089] 6 parts of diazepam;

[0090] 4.5 parts of malt selenium;

[0091] Vitamin E 4.5 parts;

[0092] 30 parts of filler;

[0093] 5 parts rapeseed oil;

[0094] 6 parts of acetone;

[0095] 140 parts of deionized water;

[0096] Specifically, the filling agent includes a sweetener, a flavoring agent, and a glue agent, and their mass ratio is 3:5:2.

[0097] Specifically, the sweetener is a composition of protein sugar, xylitol and stevioside, and their mass ratio is 2:1:1;

[0098] The aromatic agent is banana essence;

[0099] The glue is a combination of sodium carboxymethylcellulose and sodium alginate, and their mass ratio is 3:2.

[0100] The preparation method of above-mentioned niraparib oral liquid comprises the steps:

[0101] (i) Take powdered niraparib, diazepam, vitamin E and malt selenium respectively, pulverize niraparib, diaze...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a niraparib oral liquid and a preparation method thereof and belongs to the field of drug production. The niraparib oral liquid comprises the following components in parts by weight: 10-20 parts of niraparib, 4-8 parts of diazepam, 3-6 parts of malt selenium, 3-6 parts of vitamin E, 20-40 parts of filler, 3-6 parts of colza oil, 4-8 parts of acetone and 130-150 parts of deionized water. The preparation method comprises the following steps: respectively corresponding dissolving diazepam and vitamin E in acetone and colza oil; uniformly mixing niraparib, deionized water and a part of filler; adding the prepared diazepam solution and vitamin E solution; adding malt selenium and the remaining filler, uniformly mixing and then filling, instantly sterilizing and packing,thereby acquiring the niraparib oral liquid. The niraparib oral liquid disclosed by the invention is capable of boosting the niraparib to exert anticancer curative effect and reducing the adverse reactions thereof.

Description

technical field [0001] The invention relates to the field of medicine production, in particular to a niraparib oral liquid and a preparation method thereof. Background technique [0002] Niraparib (Niraparib) is an oral poly ADP-ribose polymerase (PARP) inhibitor, mainly targeting cancers with BRCA1 / 2 gene mutations, developed for ovarian cancer and breast cancer. Niraparib inhibits the repair of cells to DNA damage. For cancer cells with BRCA gene mutations, if PARP activity is further inhibited, a large amount of DNA damage will be generated when these cells divide, leading to the death of cancer cells. The chemical name of Nirapa is 2-[4-((3S)-3-piperidinyl)phenyl]-2H-indazole-7-carboxamide, which was developed by Merck and later transferred to American Biotechnology The company Tesaro, which announced the phase III clinical data of niraparib for advanced ovarian cancer, showed extremely good efficacy. [0003] Niraparib capsules were approved for marketing in the Unite...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K31/454A61K36/8998A61P35/00B67C3/24B67C3/26B67C3/22A61K31/5513A61K31/355A61K33/04
CPCA61K9/0095A61K31/355A61K31/454A61K31/5513A61K33/04A61K36/8998A61P35/00B67C3/22B67C3/24B67C3/26A61K2300/00
Inventor 汪善和钱学忠
Owner 南京瑄宇医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap